Drug Landscape ›
Estradiol Ring ›
Regulatory · United States
Marketing authorisations
FDA — authorised 26 April 1996
Application: NDA020472
Marketing authorisation holder: PFIZER
Local brand name: ESTRING
Indication: INSERT, EXTENDED RELEASE — VAGINAL
Status: approved
Read official source →
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 10
Most-reported reactions
Biliary Tract Infection — 1 report (10%) Cerebrovascular Accident — 1 report (10%) Diabetes Mellitus — 1 report (10%) Hepatic Cancer — 1 report (10%) Hepatic Infection — 1 report (10%) Intra-Abdominal Fluid Collection — 1 report (10%) Pulmonary Embolism — 1 report (10%) Pulmonary Oedema — 1 report (10%) Sepsis — 1 report (10%) Treatment Failure — 1 report (10%)
Source database →
Estradiol Ring in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Estradiol Ring approved in United States?
Yes. FDA authorised it on 26 April 1996; FDA has authorised it.
Who is the marketing authorisation holder for Estradiol Ring in United States?
PFIZER holds the US marketing authorisation.